Most investors don’t know it, but wholesaling used cars is a red-hot business. This is why Cop...
Stephen Biggar - Argus Research
02/22/2017 10:16 am EST
Vickers Stock Research, Argus’ sister company, calculates proprietary Sell/Buy Ratios using data from recent Form-4 filings (through which insiders register purchases and sales of their stock with the SEC).
Insiders at Athersys (ATHX), have recently taken advantage of the company offering a total of 22,772,300 shares at an offering price of $1.01. On the first of February, insiders purchased a total of 282,500 shares.
The ATHX share price fell sharply following the release of third-quarter results on November 9, when the company provided updates on various agreements, clinical trials and discussions with regulators.
In the fourth quarter of 2016, Athersys received a $0.6 million development milestone from Bristol-Myers Squibb (BMY) related to a legacy drug target program.
Also, a large group of insiders at Novavax (NVAX) have increased their holdings. Since the collapse of the share price in September, insiders have acquired a total of 287,994 shares. Purchasers include the SVP & CFO; SVP & General Counsel; SVP of Commercial Operations; President of R&D; and several Directors.
The company describes itself as a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. It says that it is working on a groundbreaking innovation that improves global health through safe and effective vaccines.
Related Articles on STOCKS
That doesn’t mean Best Buy (BBY), Target (TGT), Macy’s (M), Home Depot (HD) or others ar...
For those new to trading, new to me, or my methodology, I think the following ground rules will help...
When it comes to new technology, nothing’s quite as cutting edge as driverless cars, or autono...